{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T11:00:46Z","timestamp":1790938846115,"version":"4.1.0"},"reference-count":54,"publisher":"Becaris Publishing Limited","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2026,10]]},"abstract":"\n Aim:<\/jats:bold>\n Paroxysmal nocturnal hemoglobinuria (PNH) is an ultra-rare hematological condition, which if undertreated, is associated with significant morbidity and early mortality. This indirect treatment comparison (ITC) evaluated the effectiveness of pegcetacoplan (the first approved proximal inhibitor) versus crovalimab, a new C5i inhibitor (C5i), for treatment of PNH in C5i-naive and C5i-experienced patients.\n Materials & methods:<\/jats:bold>\n In the C5i-naive, an unanchored matching-adjusted indirect comparison (MAIC) was conducted with patient-level data for pegcetacoplan-versus-best-supportive-care from PRINCE (\n NCT0408560<\/jats:ext-link>\n ) and published data for crovalimab-versus-eculizumab from COMMODORE 2 (\n NCT04434092<\/jats:ext-link>\n )\/COMMODORE 3 (\n NCT04654468<\/jats:ext-link>\n ). In the C5i-experienced ITC (Bucher\u2019s method), patient-level data were from PEGASUS (\n NCT03500549<\/jats:ext-link>\n ; pegcetacoplan vs eculizumab) and aggregated data from COMMODORE 1 (\n NCT04432584<\/jats:ext-link>\n ; crovalimab-vs-eculizumab). Evaluated outcomes in both settings included red-blood-cell transfusion-avoidance; hemoglobin (Hb) stabilization; hemolysis control; mean change-from-baseline on Functional Assessment of Chronic Illness Therapy\u2013Fatigue total scores; additionally, the C5i-experienced ITC evaluated, mean change-from-baseline to week-25 for red blood cell units and domain scores on the European Organization for Research and Treatment of Cancer instrument.\n Results:<\/jats:bold>\n Pegcetacoplan versus crovalimab in the C5i-naive was associated with significantly (p\u00a0<\u00a00.05) higher probabilities of transfusion-avoidance and Hb stabilization, and greater odds of hemolysis control. In the C5i-experienced, all outcomes significantly (p\u00a0<\u00a00.05) favored pegcetacoplan.\n Conclusion:<\/jats:bold>\n Pegcetacoplan provides high clinical advantages across the full PNH treatment pathway.\n <\/jats:p>","DOI":"10.57264\/cer-2026-0015","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T15:59:38Z","timestamp":1787587178000},"source":"Crossref","is-referenced-by-count":0,"title":["Indirect treatment comparisons find enhanced effectiveness of pegcetacoplan versus crovalimab in both complement inhibitor-na\u00efve and -experienced patients with paroxysmal nocturnal hemoglobinuria"],"prefix":"10.57264","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9011-4268","authenticated-orcid":false,"given":"Raymond Siu","family":"Ming Wong","sequence":"first","affiliation":[{"name":"Sir Y.K. Pao for Cancer & Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8732-8249","authenticated-orcid":false,"given":"Koo","family":"Wilson","sequence":"additional","affiliation":[{"name":"Swedish Orphan Biovitrum AB (Sobi), Stokholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5835-8599","authenticated-orcid":false,"given":"Zalmai","family":"Hakimi","sequence":"additional","affiliation":[{"name":"Swedish Orphan Biovitrum AB (Sobi), Stokholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8652-6749","authenticated-orcid":false,"given":"Mikolaj","family":"Parkitny","sequence":"additional","affiliation":[{"name":"Clever-Access, Krakow, PolandPiotr Wojciechowski"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8400-1171","authenticated-orcid":false,"given":"Piotr","family":"Wojciechowski","sequence":"additional","affiliation":[{"name":"Clever-Access, Krakow, PolandPiotr Wojciechowski"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9740-6757","authenticated-orcid":false,"given":"Catherine","family":"Flynn","sequence":"additional","affiliation":[{"name":"St James's Hospital, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3502-3953","authenticated-orcid":false,"given":"Francis","family":"Fatoye","sequence":"additional","affiliation":[{"name":"Manchester Metropolitan University, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"key":"e_1_3_9_2_2","doi-asserted-by":"crossref","first-page":"613","DOI":"10.2147\/JBM.S431493","article-title":"Paroxysmal nocturnal haemoglobinuria: current management, unmet needs, and recommendations","volume":"14","author":"Oliver M","year":"2023","unstructured":"Oliver M, Patriquin C. Paroxysmal nocturnal haemoglobinuria: current management, unmet needs, and recommendations. J. Blood Med. 14, 613\u2013628 (2023).","journal-title":"J. Blood Med."},{"issue":"3","key":"e_1_3_9_3_2","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/ejh.12543","article-title":"Pathophysiology, diagnosis, and treatment of paroxysmal nocturnal haemoglobinuria: a review","volume":"95","author":"Devalet B","year":"2015","unstructured":"Devalet B, Mullier F, Chatelain B, Dogn\u00e9 JM, Chatelain C. Pathophysiology, diagnosis, and treatment of paroxysmal nocturnal haemoglobinuria: a review. Eur. J. Haematol. 95(3), 190\u2013198 (2015).","journal-title":"Eur. J. Haematol."},{"issue":"7","key":"e_1_3_9_4_2","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1080\/17512433.2022.2109462","article-title":"The role of the alternative pathway in paroxysmal nocturnal haemoglobinuria and emerging treatments","volume":"15","author":"Lee JW","year":"2022","unstructured":"Lee JW, Brodsky RA, Nishimura JI, Kulasekararaj AG. The role of the alternative pathway in paroxysmal nocturnal haemoglobinuria and emerging treatments. Expert Rev. Clin. Pharmacol. 15(7), 851\u2013861 (2022).","journal-title":"Expert Rev. Clin. Pharmacol."},{"issue":"1","key":"e_1_3_9_5_2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s12026-011-8239-5","article-title":"Membrane attack by complement: the assembly and biology of terminal complement complexes","volume":"51","author":"Tegla CA","year":"2011","unstructured":"Tegla CA, Cudrici C, Patel S Membrane attack by complement: the assembly and biology of terminal complement complexes. Immunol. Res. 51(1), 45\u201360 (2011).","journal-title":"Immunol. Res."},{"key":"e_1_3_9_6_2","volume-title":"Immunobiology: the immune system in health and disease","author":"Janeway CA","year":"2001","unstructured":"Janeway CA Jr, Travers P, Walport M, Shlomchik MJ. Immunobiology: the immune system in health and disease. NY, USA (2001)."},{"key":"e_1_3_9_7_2","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.3389\/fimmu.2019.01157","article-title":"Anti-complement treatment for paroxysmal nocturnal haemoglobinuria: time for proximal complement inhibition? A position paper from the SAAWP of the EBMT","volume":"10","author":"Risitano AM","year":"2019","unstructured":"Risitano AM, Marotta S, Ricci P Anti-complement treatment for paroxysmal nocturnal haemoglobinuria: time for proximal complement inhibition? A position paper from the SAAWP of the EBMT. Front. Immunol. 10, 1157 (2019).","journal-title":"Front. Immunol."},{"issue":"19","key":"e_1_3_9_8_2","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1056\/NEJM199511093331904","article-title":"Natural history of paroxysmal nocturnal haemoglobinuria","volume":"333","author":"Hillmen P","year":"1995","unstructured":"Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural history of paroxysmal nocturnal haemoglobinuria. N. Engl. J. Med. 333(19), 1253\u20131258 (1995).","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"e_1_3_9_9_2","doi-asserted-by":"crossref","first-page":"587","DOI":"10.7326\/0003-4819-148-8-200804150-00003","article-title":"Narrative Review: paroxysmal nocturnal haemoglobinuria: the physiology of complement-related hemolytic anemia","volume":"148","author":"Brodsky RA","year":"2008","unstructured":"Brodsky RA. Narrative Review: paroxysmal nocturnal haemoglobinuria: the physiology of complement-related hemolytic anemia. Ann. Intern. Med. 148(8), 587\u2013595 (2008).","journal-title":"Ann. Intern. Med."},{"issue":"1","key":"e_1_3_9_10_2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1586\/17474086.2.1.7","article-title":"Eculizumab opens a new era of treatment for paroxysmal nocturnal haemoglobinuria","volume":"2","author":"Schrezenmeier H","year":"2009","unstructured":"Schrezenmeier H, H\u00f6chsmann B. Eculizumab opens a new era of treatment for paroxysmal nocturnal haemoglobinuria. Expert Rev. Hematol. 2(1), 7\u201316 (2009).","journal-title":"Expert Rev. Hematol."},{"issue":"17","key":"e_1_3_9_11_2","doi-asserted-by":"crossref","first-page":"4094","DOI":"10.1182\/blood-2008-11-189944","article-title":"Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal haemoglobinuria patients treated by eculizumab","volume":"113","author":"Risitano AM","year":"2009","unstructured":"Risitano AM, Notaro R, Marando L Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal haemoglobinuria patients treated by eculizumab. Blood 113(17), 4094\u20134100 (2009).","journal-title":"Blood"},{"key":"e_1_3_9_12_2","doi-asserted-by":"crossref","first-page":"101041","DOI":"10.1016\/j.blre.2023.101041","article-title":"Biomarkers and laboratory assessments for monitoring the treatment of patients with paroxysmal nocturnal haemoglobinuria: differences between terminal and proximal complement inhibition","volume":"59","author":"Kulasekararaj AG","year":"2023","unstructured":"Kulasekararaj AG, Kuter DJ, Griffin M, Weitz IC, R\u00f6th A. Biomarkers and laboratory assessments for monitoring the treatment of patients with paroxysmal nocturnal haemoglobinuria: differences between terminal and proximal complement inhibition. Blood Rev. 59, 101041 (2023).","journal-title":"Blood Rev."},{"issue":"3","key":"e_1_3_9_13_2","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/ajh.27215","article-title":"The inhibition of several components of terminal complement pathway results in C3 binding to PNH red blood cells","volume":"99","author":"Sica M","year":"2024","unstructured":"Sica M, Notaro R. The inhibition of several components of terminal complement pathway results in C3 binding to PNH red blood cells. Am. J. Hematol. 99(3), 505\u2013507 (2024).","journal-title":"Am. J. Hematol."},{"issue":"11","key":"e_1_3_9_14_2","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa2029073","article-title":"Pegcetacoplan versus eculizumab in paroxysmal nocturnal haemoglobinuria","volume":"384","author":"Hillmen P","year":"2021","unstructured":"Hillmen P, Szer J, Weitz I Pegcetacoplan versus eculizumab in paroxysmal nocturnal haemoglobinuria. N. Engl. J. Med. 384(11), 1028\u20131037 (2021).","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"e_1_3_9_15_2","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/ejh.13816","article-title":"The burden of illness of patients with paroxysmal nocturnal haemoglobinuria receiving C5 inhibitors in France, Germany and the United Kingdom: patient-reported insights on symptoms and quality of life","volume":"109","author":"Panse J","year":"2022","unstructured":"Panse J, Sicre de Fontbrune F, Burmester P The burden of illness of patients with paroxysmal nocturnal haemoglobinuria receiving C5 inhibitors in France, Germany and the United Kingdom: patient-reported insights on symptoms and quality of life. Eur. J. Haematol. 109(4), 351\u2013363 (2022).","journal-title":"Eur. J. Haematol."},{"issue":"12","key":"e_1_3_9_16_2","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1182\/blood.2023021762","article-title":"Treatment outcomes of complement protein C5 inhibition in 509 UK patients with paroxysmal nocturnal haemoglobinuria","volume":"143","author":"Kelly RJ","year":"2024","unstructured":"Kelly RJ, Holt M, Vidler J Treatment outcomes of complement protein C5 inhibition in 509 UK patients with paroxysmal nocturnal haemoglobinuria. Blood 143(12), 1157\u20131166 (2024).","journal-title":"Blood"},{"issue":"12","key":"e_1_3_9_17_2","doi-asserted-by":"crossref","first-page":"S278","DOI":"10.1016\/j.jval.2024.10.1445","article-title":"HPR18 Unmet medical need in patients with paroxysmal nocturnal haemoglobinuria treated with complement 5 inhibitors: results from a cross-sectional survey in Canada","volume":"27","author":"Constantin J","year":"2024","unstructured":"Constantin J, Connolly D, Taylor Y, Hatchell N, Wiyani A, Balp MM. HPR18 Unmet medical need in patients with paroxysmal nocturnal haemoglobinuria treated with complement 5 inhibitors: results from a cross-sectional survey in Canada. Value Health 27(Suppl. 12), S278 (2024).","journal-title":"Value Health"},{"issue":"10","key":"e_1_3_9_18_2","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1038\/s41409-021-01372-0","article-title":"Categorizing hematological response to eculizumab in paroxysmal nocturnal haemoglobinuria: a multicenter real-life study","volume":"56","author":"Debureaux PE","year":"2021","unstructured":"Debureaux PE, Kulasekararaj AG, Cacace F Categorizing hematological response to eculizumab in paroxysmal nocturnal haemoglobinuria: a multicenter real-life study. Bone Marrow Transplant. 56(10), 2600\u20132602 (2021).","journal-title":"Bone Marrow Transplant."},{"issue":"6","key":"e_1_3_9_19_2","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/ejh.13946","article-title":"Nationwide study of eculizumab in paroxysmal nocturnal haemoglobinuria: evaluation of treatment indications and outcomes","volume":"110","author":"Schaap CCM","year":"2023","unstructured":"Schaap CCM, Heubel-Moenen FCJI, Nur E Nationwide study of eculizumab in paroxysmal nocturnal haemoglobinuria: evaluation of treatment indications and outcomes. Eur. J. Haematol. 110(6), 648\u2013658 (2023).","journal-title":"Eur. J. Haematol."},{"issue":"1","key":"e_1_3_9_20_2","first-page":"1140","article-title":"The burden of illness of patients with paroxysmal nocturnal haemoglobinuria receiving C5 inhibitors: clinical outcomes and medical encounters from the patient perspective","volume":"27","author":"Sicre de Fontbrune F","year":"2022","unstructured":"Sicre de Fontbrune F, Burmester P, Piggin M The burden of illness of patients with paroxysmal nocturnal haemoglobinuria receiving C5 inhibitors: clinical outcomes and medical encounters from the patient perspective. Hematol. Amst. Neth. 27(1), 1140\u20131151 (2022).","journal-title":"Hematol. Amst. Neth."},{"issue":"17","key":"e_1_3_9_21_2","doi-asserted-by":"crossref","first-page":"9477","DOI":"10.3390\/ijms25179477","article-title":"Navigating the complement pathway to optimize PNH treatment with pegcetacoplan and other currently approved complement inhibitors","volume":"25","author":"Hillmen P","year":"2024","unstructured":"Hillmen P, Horneff R, Yeh M, Kolev M, Deschatelets P. Navigating the complement pathway to optimize PNH treatment with pegcetacoplan and other currently approved complement inhibitors. Int. J. Mol. Sci. 25(17), 9477 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"e_1_3_9_22_2","unstructured":"US Food and Drug Administration. Prescribing Information: EMPAVELI\u2122 (pegcetacoplan) injection for subcutaneous use. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/215014s000lbl.pdf"},{"key":"e_1_3_9_23_2","unstructured":"European Medicines Agency. Summary of product characteristics: Aspaveli. (Accessed 16 May 2025). https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/aspaveli"},{"key":"e_1_3_9_24_2","unstructured":"Pegcetacoplan (Empaveli): CADTH reimbursement recommendation: indication: for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have an inadequate response to or are intolerant of a C5 inhibitor. Canadian Agency for Drugs and Technologies in Health. (2023). (Accessed 16 May 2024). http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK596605\/"},{"key":"e_1_3_9_25_2","unstructured":"Center for Drug Evaluation and Research. FDA approves new treatment for adults with serious rare blood disease. Published online September 30 2021. (Accessed 16 May 2025). https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-new-treatment-adults-serious-rare-blood-disease"},{"key":"e_1_3_9_26_2","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1182\/blood-2021-147493","article-title":"Efficacy and safety of pegcetacoplan treatment in complement-inhibitor na\u00efve patients with paroxysmal nocturnal haemoglobinuria: results from the Phase III Prince study","volume":"138","author":"Wong RS","year":"2021","unstructured":"Wong RS, Navarro JR, Comia NS Efficacy and safety of pegcetacoplan treatment in complement-inhibitor na\u00efve patients with paroxysmal nocturnal haemoglobinuria: results from the Phase III Prince study. Blood 138, 606 (2021).","journal-title":"Blood"},{"issue":"5","key":"e_1_3_9_27_2","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1007\/s12325-024-02827-8","article-title":"Safety and efficacy of pegcetacoplan in adult patients with paroxysmal nocturnal haemoglobinuria over 48 weeks: 307 open-label extension study","volume":"41","author":"Patriquin CJ","year":"2024","unstructured":"Patriquin CJ, Bogdanovic A, Griffin M Safety and efficacy of pegcetacoplan in adult patients with paroxysmal nocturnal haemoglobinuria over 48 weeks: 307 open-label extension study. Adv. Ther. 41(5), 2050 (2024).","journal-title":"Adv. Ther."},{"issue":"1","key":"e_1_3_9_28_2","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1182\/blood-2023-181054","article-title":"Efficacy and safety is maintained in adult patients with paroxysmal nocturnal haemoglobinuria receiving pegcetacoplan for up to 3 years","volume":"142","author":"de Castro CM","year":"2023","unstructured":"de Castro CM, Mulherin B, Patriquin CJ Efficacy and safety is maintained in adult patients with paroxysmal nocturnal haemoglobinuria receiving pegcetacoplan for up to 3 years. Blood 142(Suppl. 1), 574 (2023).","journal-title":"Blood"},{"issue":"5","key":"e_1_3_9_29_2","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1002\/ajh.27242","article-title":"Real-world experience of pegcetacoplan in paroxysmal nocturnal haemoglobinuria","volume":"99","author":"Griffin M","year":"2024","unstructured":"Griffin M, Kelly R, Brindel I Real-world experience of pegcetacoplan in paroxysmal nocturnal haemoglobinuria. Am. J. Hematol. 99(5), 816\u2013823 (2024).","journal-title":"Am. J. Hematol."},{"issue":"1","key":"e_1_3_9_30_2","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1182\/blood-2024-199472","article-title":"Efficacy and safety of pegcetacoplan in PNH patients with extra-vascular hemolysis under anti-C5: the real-life experience of the National French Reference Center","volume":"144","author":"Sicre de Fontbrune F","year":"2024","unstructured":"Sicre de Fontbrune F, Forcade E, Terriou L Efficacy and safety of pegcetacoplan in PNH patients with extra-vascular hemolysis under anti-C5: the real-life experience of the National French Reference Center. Blood 144(Suppl. 1), 1321 (2024).","journal-title":"Blood"},{"key":"e_1_3_9_31_2","volume-title":"EHA","author":"Vallejo Llamas JC","year":"2024","unstructured":"Vallejo Llamas JC, Gonz\u00e1lez C, Fern\u00e1ndez A P1917 Real-world experience of pegcetacoplan treatment in patients with paroxysmal nocturnalhaemoglobinuria (PNH) with unsatisfactory response to previous therapeutic approaches. Presented at: EHA (2024). https:\/\/library.ehaweb.org\/eha\/2024\/eha2024-congress\/420004\/juan.carlos.vallejo.llamas.real-world.experience.of.pegcetacoplan.treatment.in.html"},{"issue":"16","key":"e_1_3_9_32_2","doi-asserted-by":"crossref","first-page":"8698","DOI":"10.3390\/ijms25168698","article-title":"Three years on: the role of pegcetacoplan in paroxysmal nocturnal haemoglobinuria (PNH) since its initial approval","volume":"25","author":"Horneff R","year":"2024","unstructured":"Horneff R, Czech B, Yeh M, Surova E. Three years on: the role of pegcetacoplan in paroxysmal nocturnal haemoglobinuria (PNH) since its initial approval. Int. J. Mol. Sci. 25(16), 8698 (2024).","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"e_1_3_9_33_2","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/ejh.14139","article-title":"Pegcetacoplan in paroxysmal nocturnal haemoglobinuria: its use, its clinical effectiveness, and its influence on health-related quality of life and productivity","volume":"112","author":"Wilson K","year":"2024","unstructured":"Wilson K, Rich C, Hakimi Z Pegcetacoplan in paroxysmal nocturnal haemoglobinuria: its use, its clinical effectiveness, and its influence on health-related quality of life and productivity. Eur. J. Haematol. 112(4), 516\u2013529 (2024).","journal-title":"Eur. J. Haematol."},{"issue":"4","key":"e_1_3_9_34_2","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/bjh.20025","article-title":"Real-world evidence of pegcetacoplan in patients with paroxysmal nocturnal haemoglobinuria: a nationwide Italian study","volume":"206","author":"Metafuni E","year":"2025","unstructured":"Metafuni E, Brioschi FA, Patriarca A Real-world evidence of pegcetacoplan in patients with paroxysmal nocturnal haemoglobinuria: a nationwide Italian study. Br. J. Haematol. 206(4), 1246\u20131249 (2025).","journal-title":"Br. J. Haematol."},{"issue":"12","key":"e_1_3_9_35_2","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1182\/blood.2019003399","article-title":"The complement C5 inhibitor crovalimab in paroxysmal nocturnal haemoglobinuria","volume":"135","author":"R\u00f6th A","year":"2020","unstructured":"R\u00f6th A, Nishimura J-I, Nagy Z The complement C5 inhibitor crovalimab in paroxysmal nocturnal haemoglobinuria. Blood 135(12), 912\u2013920 (2020).","journal-title":"Blood"},{"key":"e_1_3_9_36_2","unstructured":"Piasky | European Medicines Agency (EMA). (2024). (Accessed 5 June 2025). https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/piasky"},{"issue":"6","key":"e_1_3_9_37_2","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s12519-024-00814-1","article-title":"Prevalence of nonalcoholic fatty liver disease in pediatrics and adolescents: a systematic review and meta-analysis","volume":"20","author":"Lee EJ","year":"2024","unstructured":"Lee EJ, Choi M, Ahn SB Prevalence of nonalcoholic fatty liver disease in pediatrics and adolescents: a systematic review and meta-analysis. World J. Pediatr. 20(6), 569\u2013580 (2024).","journal-title":"World J. Pediatr."},{"issue":"6","key":"e_1_3_9_38_2","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1182\/blood-2018-09-876805","article-title":"Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study","volume":"133","author":"Kulasekararaj AG","year":"2019","unstructured":"Kulasekararaj AG, Hill A, Rottinghaus ST Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study. Blood 133(6), 540\u2013549 (2019).","journal-title":"Blood"},{"issue":"6","key":"e_1_3_9_39_2","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1182\/blood-2018-09-876136","article-title":"Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study","volume":"133","author":"Lee JW","year":"2019","unstructured":"Lee JW, Sicre de Fontbrune F, Wong Lee Lee L Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. Blood 133(6), 530\u2013539 (2019).","journal-title":"Blood"},{"key":"e_1_3_9_40_2","doi-asserted-by":"crossref","first-page":"101531","DOI":"10.1016\/j.cegh.2024.101531","article-title":"Network meta-analysis: the way forward for evidence-based decisions","volume":"26","author":"Jaiswal N","year":"2024","unstructured":"Jaiswal N, Field R. Network meta-analysis: the way forward for evidence-based decisions. Clin. Epidemiol. Glob. Health 26, 101531 (2024).","journal-title":"Clin. Epidemiol. Glob. Health"},{"issue":"2","key":"e_1_3_9_41_2","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jval.2014.01.004","article-title":"Indirect treatment comparison\/network meta-analysis study questionnaire to assess relevance and credibility to inform health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force Report","volume":"17","author":"Jansen JP","year":"2014","unstructured":"Jansen JP, Trikalinos T, Cappelleri JC Indirect treatment comparison\/network meta-analysis study questionnaire to assess relevance and credibility to inform health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force Report. Value Health 17(2), 157\u2013173 (2014).","journal-title":"Value Health"},{"key":"e_1_3_9_42_2","unstructured":"Cochrane Handbook for Systematic Reviews of Interventions. (Accessed 20 May 2024). https:\/\/training.cochrane.org\/handbook\/current"},{"key":"e_1_3_9_43_2","unstructured":"Methodological guideline for quantitative evidence synthesis: direct and indirect comparisons. (2018). (Accessed 2 April 2025). https:\/\/health.ec.europa.eu\/latest-updates\/methodological-guideline-quantitative-evidence-synthesis-direct-and-indirect-comparisons-2024-03-25_en"},{"key":"e_1_3_9_44_2","unstructured":"NICE Real-World Evidence Framework. (Accessed 2 April 2025). https:\/\/www.nice.org.uk\/corporate\/ecd9\/chapter\/overview"},{"issue":"1","key":"e_1_3_9_45_2","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1182\/blood-2022-162452","article-title":"Results from the first Phase III crovalimab (C5 Inhibitor) study (COMMODORE 3): efficacy and safety in complement inhibitor-naive patients with paroxysmal nocturnal haemoglobinuria (PNH)","volume":"140","author":"Liu H","year":"2022","unstructured":"Liu H, Xia L, Weng J Results from the first Phase III crovalimab (C5 Inhibitor) study (COMMODORE 3): efficacy and safety in complement inhibitor-naive patients with paroxysmal nocturnal haemoglobinuria (PNH). Blood 140(Suppl. 1), 714\u2013716 (2022).","journal-title":"Blood"},{"issue":"9","key":"e_1_3_9_46_2","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1002\/ajh.27413","article-title":"Phase III randomized COMMODORE 1 trial: crovalimab versus eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal haemoglobinuria","volume":"99","author":"Scheinberg P","year":"2024","unstructured":"Scheinberg P, Cl\u00e9 DV, Kim JS Phase III randomized COMMODORE 1 trial: crovalimab versus eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal haemoglobinuria. Am. J. Hematol. 99(9), 1757\u20131767 (2024).","journal-title":"Am. J. Hematol."},{"issue":"1","key":"e_1_3_9_47_2","doi-asserted-by":"crossref","first-page":"4090","DOI":"10.1182\/blood-2023-177584","article-title":"Patient-reported outcomes (PROs) in patients with paroxysmal nocturnal haemoglobinuria (PNH) treated with crovalimab and eculizumab: results from the Phase III randomized COMMODORE 2 and COMMODORE 1 trials","volume":"142","author":"Panse J","year":"2023","unstructured":"Panse J, Cermak J, Kyselova O Patient-reported outcomes (PROs) in patients with paroxysmal nocturnal haemoglobinuria (PNH) treated with crovalimab and eculizumab: results from the Phase III randomized COMMODORE 2 and COMMODORE 1 trials. Blood 142(Suppl. 1), 4090 (2023).","journal-title":"Blood"},{"issue":"2","key":"e_1_3_9_48_2","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1177\/0272989X17725740","article-title":"Methods for population-adjusted indirect comparisons in health technology appraisal","volume":"38","author":"Phillippo DM","year":"2018","unstructured":"Phillippo DM, Ades AE, Dias S, Palmer S, Abrams KR, Welton NJ. Methods for population-adjusted indirect comparisons in health technology appraisal. Med. Decis. Making 38(2), 200\u2013211 (2018).","journal-title":"Med. Decis. Making"},{"issue":"6","key":"e_1_3_9_49_2","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jval.2012.05.004","article-title":"Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research","volume":"15","author":"Signorovitch JE","year":"2012","unstructured":"Signorovitch JE, Sikirica V, Erder MH Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health 15(6), 940\u2013947 (2012).","journal-title":"Value Health"},{"issue":"3","key":"e_1_3_9_50_2","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/j.1445-5994.2012.02924.x","article-title":"Cross-sectional validation study of patient-reported outcomes in patients with paroxysmal nocturnal haemoglobinuria","volume":"43","author":"Weitz I","year":"2013","unstructured":"Weitz I, Meyers G, Lamy T Cross-sectional validation study of patient-reported outcomes in patients with paroxysmal nocturnal haemoglobinuria. Intern. Med. J. 43(3), 298\u2013307 (2013).","journal-title":"Intern. Med. J."},{"issue":"6","key":"e_1_3_9_51_2","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","article-title":"The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials","volume":"50","author":"Bucher HC","year":"1997","unstructured":"Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J. Clin. Epidemiol. 50(6), 683\u2013691 (1997).","journal-title":"J. Clin. Epidemiol."},{"issue":"8","key":"e_1_3_9_52_2","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.3346\/jkms.2024.39.e81","article-title":"Impact of lactate dehydrogenase and haemoglobin levels on clinical outcomes in patients with paroxysmal nocturnal haemoglobinuria: results from the National Korean PNH Registry","volume":"39","author":"Jang JH","year":"2024","unstructured":"Jang JH, Kim JS, Lim CTK Impact of lactate dehydrogenase and haemoglobin levels on clinical outcomes in patients with paroxysmal nocturnal haemoglobinuria: results from the National Korean PNH Registry. J. Korean Med. Sci. 39(8), e81 (2024).","journal-title":"J. Korean Med. Sci."},{"issue":"25","key":"e_1_3_9_53_2","doi-asserted-by":"crossref","first-page":"6786","DOI":"10.1182\/blood-2011-02-333997","article-title":"Long-term treatment with eculizumab in paroxysmal nocturnal haemoglobinuria: sustained efficacy and improved survival","volume":"117","author":"Kelly RJ","year":"2011","unstructured":"Kelly RJ, Hill A, Arnold LM Long-term treatment with eculizumab in paroxysmal nocturnal haemoglobinuria: sustained efficacy and improved survival. Blood 117(25), 6786\u20136792 (2011).","journal-title":"Blood"},{"issue":"2","key":"e_1_3_9_54_2","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/bjh.17860","article-title":"Lactate dehydrogenase versus haemoglobin: which one is the better marker in paroxysmal nocturnal haemoglobinuria?","volume":"196","author":"Brodsky RA","year":"2022","unstructured":"Brodsky RA, Lee JW, Nishimura J-I, Szer J. Lactate dehydrogenase versus haemoglobin: which one is the better marker in paroxysmal nocturnal haemoglobinuria? Br. J. Haematol. 196(2), 264\u2013265 (2022).","journal-title":"Br. J. Haematol."},{"issue":"9","key":"e_1_3_9_55_2","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.jval.2024.05.015","article-title":"A targeted review of worldwide indirect treatment comparison guidelines and best practices","volume":"27","author":"Tanaka S","year":"2024","unstructured":"Tanaka S, Igarashi A, Moor RD A targeted review of worldwide indirect treatment comparison guidelines and best practices. Value Health 27(9), 1179\u20131190 (2024).","journal-title":"Value Health"}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2026-0015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:43:39Z","timestamp":1790937819000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2026-0015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":54,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.57264\/cer-2026-0015"],"URL":"https:\/\/doi.org\/10.57264\/cer-2026-0015","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]},"article-number":"e260015"}}